Obtain and produce new biopharmaceuticals for the treatment of cancer and other chronic noncommunicable diseases and introduce them to the Cuban Public Health. Make the scientific and productive activity economically sustainable and make contributions to the economy of the country.
To be the Latin American and Caribbean company with the greatest impact on the survival of cancer and other chronic noncommunicable diseases and with high corporate responsibility regarding the economy of the country and its stakeholders. Become an international reference biotechnology company developing a business culture of excellence based on innovation, diversification and dedication to work.
The CIM promotes the following values:
· The CIM is a bulwark of the revolution and socialism
· Real and competitive science
· Consecration to work
· Simplicity and accessibility of bosses
· Creative environment
· Transparent debate
· Culture of Quality
The CIM in its 20th Anniversary (2014) is an organization of organizations with more than 1100 workers, with highly qualified personnel composed of 41 Doctors and 150 Master of Sciences, which mostly comprise the two Scientific Councils of the Center. With 4 large production facilities, complex and geographically distributed in: Havana (EPOVAC-ANTYTER), Santiago de Cuba (LABEX) and Beijing, China (BIOTECH-BPL), connected to the National Health System through 80 clinical trials involving to more than 55 hospitals in the 15 provinces. It also has a Marketing Agency, CIMAB S.A. It carries out activities in all continents with current contracts with more than 45 companies that reach 100 countries, export operations in more than 30 countries, 3 joint ventures (China, Argentina and Singapore) and consolidated trade associations and growth in emerging countries such as Brazil, India, Southeast Asia and China
¡Stay informed of our latest news!
CIMAvax EGF ® is a therapeutic vaccine registered in Cuba (developed by the Center of Molecular Immunology (CIM), for advanced lung cancer. This therapeutic vaccine has a health history in the indication: Advanced non-small cell lung cancer (NSCLC) stage IIIb and IV, after the first line of chemotherapy. It is in this condition and type of lung cancer that the greatest clinical benefit is obtained in terms of increased survival and improved quality of life, as well as a broad safety profile in treated patients. This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary pulmonary, because we have no evidence of efficacy to date. It is necessary to know the histology and tumor stage of the patient, since CIMAvax EGF ® is only registered for non-small cell lung cancer of advanced stage IIIb and IV cells (NSCLC), in other types of tumors we have no evidence of clinical efficacy .
Questions of Interest:
Position of CIM for CIMAvax EGF®:
The Center for Molecular Immunology (CIM) is the center where it develops, produces and markets this medicine among other biotechnological products. This institution does not offer treatments to patients directly, nor does it inform about the price of the products they produce.
Foreign patients should contact the Cuban Medical Services who will evaluate each case if they are susceptible to treatment with these vaccines and receive it within a comprehensive program of patient care with commercial value.
You can contact them at these addresses:
At the International Clinic La Pradera:
Phones (537) 2737467 ext. 403
If you want a treatment outside of Cuba:
Laboratorio Libra Paraguay S.A
Dirección: Pedro Ciancio 1443 entre Santiago y San Cosme B Jara Asunción Persona de Contacto: Sr. Pablo Moreira Gerente Comercial
Correo electrónico: email@example.com
Teléfono: (595-21) 228 370
Móvil: (595) 986 679300
Sr. Alejandro Castaño.
Tel: + 57-4-334 40 33
Móvil: +57 - 311 301 8257
Cra.46 # 19 sur 117
Medellín, Colombia, América del Sur
Laboratorio Elea Phoenix S.A.
Sanabria 2353 (C1417AZE), Ciudad Autónoma de Buenos Aires, Argentina
Tel. (5411) 4379 4300 (int. 1266)
Director médico Dr. Matias DEPRATI
050033, Almaty, Khodzhanova street, 13 house, 69
CEO. Alina Ilimbayeva
+7 701 715 6000
Kraljice Natalije 46
Tel: +381 11 36 28 433
CEO. Mr. Zoran Vujovic.
Si necesita cualquier información adicional, no dude en contactarnos.